Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions.
Biomarker
CRP
Immune system
MRI
Neuropathology
RBANS
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
10
2020
accepted:
03
02
2021
pubmed:
25
3
2021
medline:
15
12
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
While the biological substrates of brain and behavioural changes in persons with schizophrenia remain unclear, increasing evidence implicates that inflammation is involved. In schizophrenia, including first-episode psychosis and anti-psychotic naïve patients, there are numerous reports of increased peripheral inflammation, cognitive deficits and neuropathologies such as cortical thinning. Research defining the relationship between inflammation and schizophrenia symptomatology and neuropathology is needed. Therefore, we analysed the level of C-reactive protein (CRP), a peripheral inflammation marker, and its relationship with cognitive functioning in a cohort of 644 controls and 499 schizophrenia patients. In a subset of individuals who underwent MRI scanning (99 controls and 194 schizophrenia cases), we tested if serum CRP was associated with cortical thickness. CRP was significantly increased in schizophrenia patients compared to controls, co-varying for age, sex, overweight/obesity and diabetes (p < 0.006E-10). In schizophrenia, increased CRP was mildly associated with worse performance in attention, controlling for age, sex and education (R =- 0.15, p = 0.001). Further, increased CRP was associated with reduced cortical thickness in three regions related to attention: the caudal middle frontal, the pars opercularis and the posterior cingulate cortices, which remained significant after controlling for multiple comparisons (all p < 0.05). Together, these findings indicate that increased peripheral inflammation is associated with deficits in cognitive function and brain structure in schizophrenia, especially reduced attention and reduced cortical thickness in associated brain regions. Using CRP as a biomarker of peripheral inflammation in persons with schizophrenia may help to identify vulnerable patients and those that may benefit from adjunctive anti-inflammatory treatments.
Identifiants
pubmed: 33760971
doi: 10.1007/s00406-021-01237-z
pii: 10.1007/s00406-021-01237-z
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-607Références
Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, Toovey S, Prinssen EP (2014) Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 10(11):643–660. https://doi.org/10.1038/nrneurol.2014.187
doi: 10.1038/nrneurol.2014.187
pubmed: 25311587
Schizophrenia Working Group of the Psychiatric Genomics C (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427. https://doi.org/10.1038/nature13595
doi: 10.1038/nature13595
Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2(3):258–270. https://doi.org/10.1016/S2215-0366(14)00122-9
doi: 10.1016/S2215-0366(14)00122-9
pubmed: 26359903
pmcid: 4595998
Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D (2018) Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res 192:16–29. https://doi.org/10.1016/j.schres.2017.04.015
doi: 10.1016/j.schres.2017.04.015
pubmed: 28416092
Yap SH, Moshage HJ, Hazenberg BPC, Roelofs HMJ, Bijzet J, Limburg PC, Aarden LA, Van Rijswijk MH (1991) Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochem Biophys Acta 1091(3):405–408
doi: 10.1016/0167-4889(91)90207-E
Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP (2009) CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med 7:102. https://doi.org/10.1186/1479-5876-7-102
doi: 10.1186/1479-5876-7-102
pubmed: 19948067
pmcid: 2791755
Fond G, Lancon C, Auquier P, Boyer L (2018) C-reactive protein as a peripheral biomarker in schizophrenia. An updated systematic review. Front Psychiatry 9:392. https://doi.org/10.3389/fpsyt.2018.00392
doi: 10.3389/fpsyt.2018.00392
pubmed: 30190688
pmcid: 6115522
Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, Nardin P, Gonçalves CA, Berk M (2015) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21(4):554–564. https://doi.org/10.1038/mp.2015.87
doi: 10.1038/mp.2015.87
pubmed: 26169974
Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709. https://doi.org/10.1038/mp.2016.3
doi: 10.1038/mp.2016.3
pubmed: 26903267
pmcid: 6056174
Banks WA (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11(8):973–984. https://doi.org/10.2174/1381612053381684
doi: 10.2174/1381612053381684
pubmed: 15777248
Spencer JI, Bell JS, DeLuca GC (2018) Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 89(1):42–52. https://doi.org/10.1136/jnnp-2017-316011
doi: 10.1136/jnnp-2017-316011
pubmed: 28860328
Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ (2018) The blood–brain barrier in psychosis. Lancet Psychiatry 5(1):79–92. https://doi.org/10.1016/s2215-0366(17)30293-6
doi: 10.1016/s2215-0366(17)30293-6
pubmed: 28781208
Bulzacka E, Boyer L, Schurhoff F, Godin O, Berna F, Brunel L, Andrianarisoa M, Aouizerate B, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Gloahec T, Llorca PM, Mallet J, Misdrahi D, Rey R, Richieri R, Passerieux C, Roux P, Yazbek H, Leboyer M, Fond G, Group F-S (2016) Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull 42(5):1290–1302. https://doi.org/10.1093/schbul/sbw029
doi: 10.1093/schbul/sbw029
pubmed: 27143795
pmcid: 4988740
Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93(1–3):261–265. https://doi.org/10.1016/j.schres.2007.03.022
doi: 10.1016/j.schres.2007.03.022
pubmed: 17490859
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671. https://doi.org/10.1016/j.biopsych.2011.04.013
doi: 10.1016/j.biopsych.2011.04.013
pubmed: 21641581
pmcid: 4071300
Bora E (2019) Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med 49(12):1971–1979. https://doi.org/10.1017/S0033291719001685
doi: 10.1017/S0033291719001685
pubmed: 31284882
Jacomb I, Stanton C, Vasudevan R, Powell H, O’Donnell M, Lenroot R, Bruggemann J, Balzan R, Galletly C, Liu D, Weickert CS, Weickert TW (2018) C-reactive protein: higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls. Front Immunol 9:2230. https://doi.org/10.3389/fimmu.2018.02230
doi: 10.3389/fimmu.2018.02230
pubmed: 30364161
pmcid: 6192380
Zhang Y, Catts VS, Sheedy D, McCrossin T, Kril JJ, Weickert CS (2016) Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. Transl psychiatry 6(12):e982. https://doi.org/10.1038/tp.2016.238
doi: 10.1038/tp.2016.238
pubmed: 27959331
pmcid: 5290336
Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R (2018) Plasma levels of soluble tumor necrosis factor receptor 2 (sTNFR2) are associated with hippocampal volume and cognitive performance in patients with schizophrenia. Int J Neuropsychopharmacol 21(7):631–639. https://doi.org/10.1093/ijnp/pyy013
doi: 10.1093/ijnp/pyy013
pubmed: 29529289
pmcid: 6031046
Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, Weickert CS (2016) Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry 21(8):1090–1098. https://doi.org/10.1038/mp.2015.90
doi: 10.1038/mp.2015.90
pubmed: 26194183
Lesh TA, Careaga M, Rose DR, McAllister AK, Van de Water J, Carter CS (2018) Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation 15(1):165. https://doi.org/10.1186/s12974-018-1197-2
doi: 10.1186/s12974-018-1197-2
pubmed: 29803226
pmcid: 5970482
Kalmady SV, Venkatasubramanian G, Shivakumar V, Gautham S, Subramaniam A, Jose DA, Maitra A, Ravi V, Gangadhar BN (2014) Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility? PLoS ONE. https://doi.org/10.1371/journal.pone
doi: 10.1371/journal.pone
pubmed: 24787542
pmcid: 4008499
Mondelli V, Cattaneo A, Murri MB, Di Forti M, Handley R, Hepgul N, Miorelli A, Navari S, Papadopoulos AS, Aitchison KJ, Morgan C, Murray RM, Dazzan P, Pariante CM (2011) Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 72(12):1677–1684. https://doi.org/10.4088/JCP.10m06745
doi: 10.4088/JCP.10m06745
pubmed: 21672499
pmcid: 4082665
Winkler AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT, Duggirala R, Glahn DC (2010) Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage 53(3):1135–1146. https://doi.org/10.1016/j.neuroimage.2009.12.028
doi: 10.1016/j.neuroimage.2009.12.028
pubmed: 20006715
Kochunov P, Charlesworth J, Winkler A, Hong LE, Nichols TE, Curran JE, Sprooten E, Jahanshad N, Thompson PM, Johnson MP, Kent JW Jr, Landman BA, Mitchell B, Cole SA, Dyer TD, Moses EK, Goring HH, Almasy L, Duggirala R, Olvera RL, Glahn DC, Blangero J (2013) Transcriptomics of cortical gray matter thickness decline during normal aging. Neuroimage 82:273–283. https://doi.org/10.1016/j.neuroimage.2013.05.066
doi: 10.1016/j.neuroimage.2013.05.066
pubmed: 23707588
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Bustillo JR, Clark VP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA, van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik UK, Jorgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A, Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santianez R, Tordesillas-Gutierrez D, Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens FA, Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quide Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Shannon Weickert C, Weickert TW, Morris DW, Hong E, Kochunov P, Beard LM, Gur RE, Gur RC, Satterthwaite TD, Wolf DH, Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O’Leary DS, Potkin SG, Preda A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H, Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthusen RPF, King MD, Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ, Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW, Rotenberg D, Voineskos AN, Ciufolini S, Radua J, Dazzan P, Murray R, Reis Marques T, Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher-Rossler A, Smieskova R, Alpert KI, Wang L, Jonsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun JY, Cannon DM, McDonald C, Lebedeva I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L, Karolinska Schizophrenia P, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, Hagenaars SP, McIntosh AM, Whalley HC, Lawrie SM, Knochel C, Oertel-Knochel V, Stablein M, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, Lopez-Jaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA (2018) Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. Biol Psychiatry 84(9):644–654. https://doi.org/10.1016/j.biopsych.2018.04.023
doi: 10.1016/j.biopsych.2018.04.023
pubmed: 29960671
pmcid: 6177304
Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, Sevy S, Wang Y, Schrock K, Bilder RM (2005) Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol Psychiatry 58(1):32–40. https://doi.org/10.1016/j.biopsych.2005.03.043
doi: 10.1016/j.biopsych.2005.03.043
pubmed: 15992520
Venkatasubramanian G, Jayakumar PN, Gangadhar BN, Keshavan MS (2008) Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naive schizophrenia. Acta Psychiatr Scand 117(6):420–431. https://doi.org/10.1111/j.1600-0447.2008.01198.x
doi: 10.1111/j.1600-0447.2008.01198.x
pubmed: 18479318
Crespo-Facorro B, Roiz-Santianez R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Tordesillas-Gutierrez D, Sanchez E, Tabares-Seisdedos R, Andreasen N, Magnotta V, Vazquez-Barquero JL (2011) Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychol Med 41(7):1449–1460. https://doi.org/10.1017/S003329171000200X
doi: 10.1017/S003329171000200X
pubmed: 20942995
Cannon TD, Chung Y, He G, Sun DQ, Jacobson A, van Erp TGM, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R, S NAPL (2015) Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 77(2):147–157. https://doi.org/10.1016/j.biopsych.2014.05.023
doi: 10.1016/j.biopsych.2014.05.023
pubmed: 25034946
Hartberg CB, Lawyer G, Nyman H, Jonsson EG, Haukvik UK, Saetre P, Bjerkan PS, Andreassen OA, Hall H, Agartz I (2010) Investigating relationships between cortical thickness and cognitive performance in patients with schizophrenia and healthy adults. Psychiatry Res 182(2):123–133. https://doi.org/10.1016/j.pscychresns.2010.01.001
doi: 10.1016/j.pscychresns.2010.01.001
pubmed: 20456929
Ehrlich S, Brauns S, Yendiki A, Ho BC, Calhoun V, Schulz SC, Gollub RL, Sponheim SR (2012) Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr Bull 38(5):1050–1062. https://doi.org/10.1093/schbul/sbr018
doi: 10.1093/schbul/sbr018
pubmed: 21436318
Hartberg CB, Sundet K, Rimol LM, Haukvik UK, Lange EH, Nesvag R, Dale AM, Melle I, Andreassen OA, Agartz I (2011) Brain cortical thickness and surface area correlates of neurocognitive performance in patients with schizophrenia, bipolar disorder, and healthy adults. J Int Neuropsychol Soc 17(6):1080–1093. https://doi.org/10.1017/S1355617711001081
doi: 10.1017/S1355617711001081
pubmed: 22013998
Van Rheenen TE, Cropley V, Zalesky A, Bousman C, Wells R, Bruggemann J, Sundram S, Weinberg D, Lenroot RK, Pereira A, Shannon Weickert C, Weickert TW, Pantelis C (2018) Widespread volumetric reductions in schizophrenia and schizoaffective patients displaying compromised cognitive abilities. Schizophr Bull 44(3):560–574. https://doi.org/10.1093/schbul/sbx109
doi: 10.1093/schbul/sbx109
pubmed: 28981831
Loughland C, Draganic D, McCabe K, Richards J, Nasir A, Allen J, Catts S, Jablensky A, Henskens F, Michie P, Mowry B, Pantelis C, Schall U, Scott R, Tooney P, Carr V (2010) Australian Schizophrenia Research Bank: a database of comprehensive clinical, endophenotypic and genetic data for aetiological studies of schizophrenia. Aust N Z J Psychiatry 44(11):1029–1035. https://doi.org/10.3109/00048674.2010.501758
doi: 10.3109/00048674.2010.501758
pubmed: 21034186
Randolph C, Tierney MC, Mohr E, Chase TN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20(3):310–319. https://doi.org/10.1076/jcen.20.3.310.823
doi: 10.1076/jcen.20.3.310.823
pubmed: 9845158
Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97(20):11050–11055. https://doi.org/10.1073/pnas.200033797
doi: 10.1073/pnas.200033797
pubmed: 10984517
pmcid: 27146
Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31(3):968–980. https://doi.org/10.1016/j.neuroimage.2006.01.021
doi: 10.1016/j.neuroimage.2006.01.021
pubmed: 16530430
Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47(3):426–430
doi: 10.1093/clinchem/47.3.426
Zhang T, Li H, Stone WS, Woodberry KA, Seidman LJ, Tang Y, Guo Q, Zhuo K, Qian Z, Cui H, Zhu Y, Jiang L, Chow A, Tang Y, Li C, Jiang K, Yi Z, Xiao Z, Wang J (2015) Neuropsychological impairment in prodromal, first-episode, and chronic psychosis: assessing RBANS performance. PLoS ONE 10(5):e0125784. https://doi.org/10.1371/journal.pone.0125784
doi: 10.1371/journal.pone.0125784
pubmed: 25973925
pmcid: 4431726
Wells R, Swaminathan V, Sundram S, Weinberg D, Bruggemann J, Jacomb I, Cropley V, Lenroot R, Pereira AM, Zalesky A, Bousman C, Pantelis C, Weickert CS, Weickert TW (2015) The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. NPJ Schizophr 1:15043. https://doi.org/10.1038/npjschz.2015.43
doi: 10.1038/npjschz.2015.43
pubmed: 27336046
pmcid: 4849463
Green MJ, Chia TY, Cairns MJ, Wu JQ, Tooney PA, Scott RJ, Carr VJ, Bank ASR (2014) Catechol-O-methyltransferase (COMT) genotype moderates the effects of childhood trauma on cognition and symptoms in schizophrenia. J Psychiatr Res 49:43–50. https://doi.org/10.1016/j.jpsychires.2013.10.018
doi: 10.1016/j.jpsychires.2013.10.018
pubmed: 24252819
Nani A, Manuello J, Mancuso L, Liloia D, Costa T, Cauda F (2019) The neural correlates of consciousness and attention: two sister processes of the brain. Front Neurosci 13:1169. https://doi.org/10.3389/fnins.2019.01169
doi: 10.3389/fnins.2019.01169
pubmed: 31749675
pmcid: 6842945
Zajkowska Z, Mondelli V (2014) First-episode psychosis: an inflammatory state? NeuroImmunoModulation 21(2–3):102–108. https://doi.org/10.1159/000356536
doi: 10.1159/000356536
pubmed: 24557042
Wysokinski A, Margulska A, Strzelecki D, Kloszewska I (2015) Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry 69(5):346–353. https://doi.org/10.3109/08039488.2014.984755
doi: 10.3109/08039488.2014.984755
pubmed: 25495587
Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18(2):206–214. https://doi.org/10.1038/mp.2012.110
doi: 10.1038/mp.2012.110
pubmed: 22869038
Purves-Tyson TD, Weber-Stadlbauer U, Richetto J, Rothmond DA, Labouesse MA, Polesel M, Robinson K, Shannon Weickert C, Meyer U (2019) Increased levels of midbrain immune-related transcripts in schizophrenia and in murine offspring after maternal immune activation. Mol Psychiatry. https://doi.org/10.1038/s41380-019-0434-0
doi: 10.1038/s41380-019-0434-0
pubmed: 31168068
pmcid: 7910216
Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2(5):e141. https://doi.org/10.1371/journal.pmed.0020141
doi: 10.1371/journal.pmed.0020141
pubmed: 15916472
pmcid: 1140952
Yang Y, Kozloski M (2011) Sex differences in age trajectories of physiological dysregulation: inflammation, metabolic syndrome, and allostatic load. J Gerontol A Biol Sci Med Sci 66(5):493–500. https://doi.org/10.1093/gerona/glr003
doi: 10.1093/gerona/glr003
pubmed: 21350248
Singh T, Newman AB (2011) Inflammatory markers in population studies of aging. Ageing Res Rev 10(3):319–329. https://doi.org/10.1016/j.arr.2010.11.002
doi: 10.1016/j.arr.2010.11.002
pubmed: 21145432
Kaur SS, Gonzales MM, Eagan DE, Goudarzi K, Tanaka H, Haley AP (2015) Inflammation as a mediator of the relationship between cortical thickness and metabolic syndrome. Brain Imaging Behav 9(4):737–743. https://doi.org/10.1007/s11682-014-9330-z
doi: 10.1007/s11682-014-9330-z
pubmed: 25376331
pmcid: 4424190
Corlier F, Hafzalla G, Faskowitz J, Kuller LH, Becker JT, Lopez OL, Thompson PM, Braskie MN (2018) Systemic inflammation as a predictor of brain aging: contributions of physical activity, metabolic risk, and genetic risk. Neuroimage 172:118–129. https://doi.org/10.1016/j.neuroimage.2017.12.027
doi: 10.1016/j.neuroimage.2017.12.027
pubmed: 29357308
pmcid: 5954991
Bowie CR, Harvey PD (2006) Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat 2(4):531
doi: 10.2147/nedt.2006.2.4.531
Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, Jacobs KR, Balzan R, Bruggemann J, O’Donnell M, Lenroot R, Guillemin GJ, Weickert TW (2020) Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry 25(11):2860–2872. https://doi.org/10.1038/s41380-019-0401-9
doi: 10.1038/s41380-019-0401-9
pubmed: 30940904
Cohen RA, de la Monte S, Gongvatana A, Ombao H, Gonzalez B, Devlin KN, Navia B, Tashima KT (2011) Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. J Neuroimmunol 233(1–2):204–210. https://doi.org/10.1016/j.jneuroim.2010.11.006
doi: 10.1016/j.jneuroim.2010.11.006
pubmed: 21146232
Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T (2003) Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61(1):76–80. https://doi.org/10.1212/01.wnl.0000073620.42047.d7
doi: 10.1212/01.wnl.0000073620.42047.d7
pubmed: 12847160
Teunissen CE, van Boxtel MP, Bosma H, Bosmans E, Delanghe J, De Bruijn C, Wauters A, Maes M, Jolles J, Steinbusch HW, de Vente J (2003) Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 134(1–2):142–150. https://doi.org/10.1016/s0165-5728(02)00398-3
doi: 10.1016/s0165-5728(02)00398-3
pubmed: 12507782
Kogan S, Ospina LH, Mittal VA, Kimhy D (2020) The impact of inflammation on neurocognition and risk for psychosis: a critical review. Eur Arch Psychiatry Clin Neurosci 270(7):793–802. https://doi.org/10.1007/s00406-019-01073-2
doi: 10.1007/s00406-019-01073-2
pubmed: 31620871
Caspi A, Reichenberg A, Weiser M, Rabinowitzc J, Kaplan Z, Knobler H, Davidson-Sagi N, Davidson M (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 65(2–3):87–94. https://doi.org/10.1016/S0920-9964(03)00056-2
doi: 10.1016/S0920-9964(03)00056-2
pubmed: 14630301
Lussier I, Stip E (2001) Memory and attention deficits in drug naive patients with schizophrenia. Schizophr Res 48(1):45–55. https://doi.org/10.1016/S0920-9964(00)00102-X
doi: 10.1016/S0920-9964(00)00102-X
pubmed: 11278153
Culley DJ, Snayd M, Baxter MG, Xie Z, Lee IH, Rudolph J, Inouye SK, Marcantonio ER, Crosby G (2014) Systemic inflammation impairs attention and cognitive flexibility but not associative learning in aged rats: possible implications for delirium. Front Aging Neurosci 6:107. https://doi.org/10.3389/fnagi.2014.00107
doi: 10.3389/fnagi.2014.00107
pubmed: 24959140
pmcid: 4050637
Holden JM, Meyers-Manor JE, Overmier JB, Gahtan E, Sweeney W, Miller H (2008) Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory. Behav Brain Res 194(2):138–145. https://doi.org/10.1016/j.bbr.2008.06.032
doi: 10.1016/j.bbr.2008.06.032
pubmed: 18655807
Corbetta M, Patel G, Shulman GL (2008) The reorienting system of the human brain: from environment to theory of mind. Neuron 58(3):306–324. https://doi.org/10.1016/j.neuron.2008.04.017
doi: 10.1016/j.neuron.2008.04.017
pubmed: 18466742
pmcid: 2441869
Leech R, Sharp DJ (2014) The role of the posterior cingulate cortex in cognition and disease. Brain 137(Pt 1):12–32. https://doi.org/10.1093/brain/awt162
doi: 10.1093/brain/awt162
pubmed: 23869106
Lekander M, Karshikoff B, Johansson E, Soop A, Fransson P, Lundstrom JN, Andreasson A, Ingvar M, Petrovic P, Axelsson J, Nilsonne G (2016) Intrinsic functional connectivity of insular cortex and symptoms of sickness during acute experimental inflammation. Brain Behav Immun 56:34–41. https://doi.org/10.1016/j.bbi.2015.12.018
doi: 10.1016/j.bbi.2015.12.018
pubmed: 26732827
Rosano C, Marsland AL, Gianaros PJ (2012) Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging. Aging Dis 3(1):16–33
pubmed: 22500269
Silbert LC, Lahna D, Promjunyakul NO, Boespflug E, Ohya Y, Higashiuesato Y, Nishihira J, Katsumata Y, Tokashiki T, Dodge HH (2018) Risk factors associated with cortical thickness and white matter hyperintensities in dementia free okinawan elderly. J Alzheimers Dis 63(1):365–372. https://doi.org/10.3233/JAD-171153
doi: 10.3233/JAD-171153
pubmed: 29578488
pmcid: 5900560
Cropley VL, Klauser P, Lenroot RK, Bruggemann J, Sundram S, Bousman C, Pereira A, Di Biase MA, Weickert TW, Weickert CS, Pantelis C, Zalesky A (2017) Accelerated gray and white matter deterioration with age in schizophrenia. Am J Psychiatry 174(3):286–295. https://doi.org/10.1176/appi.ajp.2016.16050610
doi: 10.1176/appi.ajp.2016.16050610
pubmed: 27919183
Zhang W, Deng W, Yao L, Xiao Y, Li F, Liu J, Sweeney JA, Lui S, Gong Q (2015) Brain structural abnormalities in a group of never-medicated patients with long-term schizophrenia. Am J Psychiatry 172(10):995–1003. https://doi.org/10.1176/appi.ajp.2015.14091108
doi: 10.1176/appi.ajp.2015.14091108
pubmed: 26085040
Hulshoff Pol HE, Schnack HG, Bertens MG, van Haren NE, van der Tweel I, Staal WG, Baare WF, Kahn RS (2002) Volume changes in gray matter in patients with schizophrenia. Am J Psychiatry 159(2):244–250. https://doi.org/10.1176/appi.ajp.159.2.244
doi: 10.1176/appi.ajp.159.2.244
pubmed: 11823266
Nenadic I, Sauer H, Smesny S, Gaser C (2012) Aging effects on regional brain structural changes in schizophrenia. Schizophr Bull 38(4):838–844. https://doi.org/10.1093/schbul/sbq140
doi: 10.1093/schbul/sbq140
pubmed: 21296908
Bauer ME, Teixeira AL (2019) Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci 1437(1):57–67. https://doi.org/10.1111/nyas.13712
doi: 10.1111/nyas.13712
pubmed: 29752710
Chang HH, Lee IH, Gean PW, Lee SY, Chi MH, Yang YK, Lu RB, Chen PS (2012) Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun 26(1):90–95. https://doi.org/10.1016/j.bbi.2011.07.239
doi: 10.1016/j.bbi.2011.07.239
pubmed: 21839826
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R (2013) Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 150(2):456–459. https://doi.org/10.1016/j.jad.2013.04.039
doi: 10.1016/j.jad.2013.04.039
pubmed: 23684514
Opel N, Cearns M, Clark S, Toben C, Grotegerd D, Heindel W, Kugel H, Teuber A, Minnerup H, Berger K, Dannlowski U, Baune BT (2019) Large-scale evidence for an association between low-grade peripheral inflammation and brain structural alterations in major depression in the BiDirect study. J Psychiatry Neurosci 44(6):423–431. https://doi.org/10.1503/jpn.180208
doi: 10.1503/jpn.180208
pubmed: 31304733
pmcid: 6821515
Chung KH, Huang SH, Wu JY, Chen PH, Hsu JL, Tsai SY (2013) The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. Neuropsychobiology 68(3):168–173
doi: 10.1159/000353613
Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM (2019) Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med 49(12):1958–1970. https://doi.org/10.1017/S0033291719001454
doi: 10.1017/S0033291719001454
pubmed: 31258105
pmcid: 6712955
Miller AH, Raison CL (2015) Are anti-inflammatory therapies viable treatments for psychiatric disorders?: where the rubber meets the road. JAMA Psychiatry 72(6):527–528. https://doi.org/10.1001/jamapsychiatry.2015.22
doi: 10.1001/jamapsychiatry.2015.22
pubmed: 25853989
pmcid: 5542670
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70(1):31–41. https://doi.org/10.1001/2013.jamapsychiatry.4
doi: 10.1001/2013.jamapsychiatry.4
pubmed: 22945416
pmcid: 4015348